EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieMultizentrische StudieOpen access · CC BY-NC-ND 4.0

Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study

Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebarao Patil, Ambrish C, Satish Babu K N, Arvind Palawat and 11 more

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6207-6216

DOI: 10.1111/dom.70778 ↗

At a glance

Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, published online on 2026-05-03. Written by Rakesh Sahay and 22 co-authors. Institution: Department of Endocrinology, Osmania General Hospital, Hyderabad, Telangana, India. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Metformin, Sitagliptin Phosphate. 20 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Sun Pharma Laboratories Limited.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D). Materials and Methods In this Phase 3, randomised, double‐blind, double‐dummy study, adult patients with T2D and glycated haemoglobin (HbA 1c ) of 8%–11%, despite treatment with metformin and glimepiride, were randomised 1:1 to triple FDC of sitagliptin 50 mg, metformin 1000 mg and glimepiride 1 mg (SITA + MET + GLIM group) or metformin 1000 mg and glimepiride 2 mg (Co‐administration group) for 16 weeks. Patients assigned to the SITA + MET + GLIM group could continue treatment for a 12‐week open‐label period. The primary endpoint was the change in HbA 1c from baseline to Week 16.

Results

Overall, 190 patients were randomised to the SITA + MET + GLIM group and 202 to the Co‐administration group. The least squares mean (standard error) change from baseline in HbA 1c at Week 16 was −1.79 (0.07%) in the SITA + MET + GLIM group and −1.27 (0.06%) in the co‐administration group (estimated treatment difference −0.51; 95% confidence interval [CI] −0.69 to −0.33; p < 0.0001). The proportion of patients with HbA 1c below 7% at Week 16 was 32.1% in the SITA + MET + GLIM group and 12.6% in the Co‐administration group ( p < 0.0001). Adverse events occurred in 25 patients (13.2%) in the SITA + MET + GLIM group and 30 patients (14.9%) in the Co‐administration group.

Conclusions

The triple FDC was superior to co‐administered metformin and high‐dose glimepiride for achieving glycaemic control and was well tolerated in Indian patients with T2D. Trial Registration Clinical Trials Registry–India identifier: CTRI/2021/11/038169 (registered on 22 November 2021); URL: https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjI1Mjk=&Enc=&userName=

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsMetforminSitagliptin PhosphateSulfonylurea CompoundsAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseDouble-Blind MethodDrug CombinationsDrug Therapy, CombinationGlycated HemoglobinHypoglycemiaIndiaInsulin SecretagoguesTreatment Outcome

Author keywords

DPP‐IV inhibitorPhase III studyType 2 diabetesantidiabetic drugclinical trialglycaemic control

Substances

Blood GlucoseDrug CombinationsglimepirideGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin SecretagoguesMetforminSitagliptin PhosphateSulfonylurea Compounds

Authors and institutions

  • Department of Endocrinology, Osmania General Hospital, Hyderabad, Telangana, India.
  • Citizen Hospital, Bengaluru, Karnataka, India.
  • Department of Medicine, Maya Hospital and Maternity Centre, Kanpur, Uttar Pradesh, India.
  • Department of Medicine, Government Medical College and Government General Hospital, Srikakulam, Andhra Pradesh, India.
  • Department of Diabetology, Kovai Diabetes Speciality Centre and Hospital, Coimbatore, Tamil Nadu, India.
  • Department of Medicine, Priyadarshani Nursing Home, Virar, Maharashtra, India.

ORCID profiles: Dipak Patil

Funding

  • Sun Pharma Laboratories Limited

Cite

APA

Sahay, R., Gowda, A., Singh, M. K., Rao, A. G., Duraisamy, R., Gangwani, D., Shukla, J., Agarwal, V., Patil, S. S., C, A., K N, S. B., Palawat, A., Gofne, S. K., Sahoo, A. K., Rai, P. K., Shaikh, R., Saha, S., Patil, D., Ghadge, P., …, & Joglekar, S. (2026). Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study. Diabetes, Obesity and Metabolism, 28(7), 6207-6216. https://doi.org/10.1111/dom.70778

Vancouver

Sahay R, Gowda A, Singh MK, Rao AG, Duraisamy R, Gangwani D, et al. Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study. Diabetes, Obesity and Metabolism. 2026;28(7):6207-6216. doi:10.1111/dom.70778

BibTeX
@article{Sahay2026,
  author = {Sahay, Rakesh and Gowda, Ambanna and Singh, Manish Kumar and Rao, A Gopal and Duraisamy, Ramesh and Gangwani, Dinesh and Shukla, Jitendra and Agarwal, Vikas and Patil, Sandesh Sahebarao and C, Ambrish and K N, Satish Babu and Palawat, Arvind and Gofne, Sandip Krishnrao and Sahoo, Abhay Kumar and Rai, Pradeep Kumar and Shaikh, Raisa and Saha, Shruti and Patil, Dipak and Ghadge, Pravin and Patel, Piyush and Lakhwani, Lalit and Mehta, Suyog and Joglekar, Sadhna},
  title = {Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {6207--6216},
  doi = {10.1111/dom.70778}
}
Start for free →